SequelSEC

Aura Biosciences, Inc. AURA

Biological Products, (No Diagnostic Substances) · CIK 0001501796 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$48.07M
Fiscal year ended 2026-06-30
Free cash flow
-$32.52M
Fiscal year ended 2026-06-30

Aura Biosciences, Inc. (AURA) reported net income of -$45.64M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aura Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Aura Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$48.07MUnavailable-$27.24M-$27.91MUnavailableUnavailable-$27.81M-$23.23MUnavailableUnavailable
Net income-$45.64MUnavailable-$25.56M-$26.13MUnavailableUnavailable-$25.83M-$21.04MUnavailableUnavailable
Research & development$30.75MUnavailable$21.90M$22.18MUnavailableUnavailable$22.33M$17.04MUnavailableUnavailable
Weighted-average diluted sharesshares 94.86MUnavailableUnavailableshares 65.94MUnavailableUnavailableUnavailableshares 49.66MUnavailableUnavailable
Pretax income-$45.61MUnavailable-$25.54M-$26.10MUnavailableUnavailable-$25.81M-$21.00MUnavailableUnavailable
Income tax expense$29.00KUnavailable$15.00K$26.00KUnavailableUnavailable$24.00K$43.00KUnavailableUnavailable
Diluted EPS$-0.48UnavailableUnavailable$-0.40UnavailableUnavailableUnavailable$-0.42UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$17.32MUnavailable$5.34M$5.73MUnavailableUnavailable$5.47M$6.20MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aura Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$67.84MUnavailable$59.52M$47.55MUnavailableUnavailable$31.69M$25.41MUnavailableUnavailable
Total assets$348.13MUnavailable$169.43M$190.02MUnavailableUnavailable$182.50M$205.34MUnavailableUnavailable
Current assets$329.03MUnavailable$149.74M$170.12MUnavailableUnavailable$160.62M$183.48MUnavailableUnavailable
Total liabilities$32.86MUnavailable$32.52M$33.36MUnavailableUnavailable$30.53M$30.67MUnavailableUnavailable
Current liabilities$19.56MUnavailable$18.38M$18.82MUnavailableUnavailable$14.91M$14.71MUnavailableUnavailable
Total equity incl. NCI$315.27MUnavailable$136.91M$156.67MUnavailableUnavailable$151.97M$174.67MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.25MUnavailable$1.55M$1.89MUnavailableUnavailable$2.30M$1.99MUnavailableUnavailable

Cash flow

Aura Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$32.50MUnavailable-$20.47M-$20.14MUnavailableUnavailable-$23.95M-$15.27MUnavailableUnavailable
Capital expenditures$21.00KUnavailable$176.00K$45.00KUnavailableUnavailable$299.00K$341.00KUnavailableUnavailable
Investing cash flow-$226.04MUnavailable$29.82M-$44.02MUnavailableUnavailable$29.70M$9.89MUnavailableUnavailable
Financing cash flow$241.75MUnavailable$2.77M$4.36MUnavailableUnavailable$543.00K$716.00KUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$6.29M-$4.67MUnavailableUnavailable
Stock-based compensation$12.37MUnavailable$3.28M$3.69MUnavailableUnavailable$2.94M$2.75MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Aura Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$32.52MUnavailable-$20.64M-$20.19MUnavailableUnavailable-$24.25M-$15.61MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio16.82xUnavailable8.15x9.04xUnavailableUnavailable10.77x12.47xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.